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Running Title: NleB glycosylates GAPDH to inhibit TRAF2/NF-B  
Summary.  
 
Modulation of NF-B-dependent responses is critical to the success of attaching/effacing (A/E) human 
pathogenic E. coli (EPEC and EHEC) and the natural mouse pathogen Citrobacter rodentium.  NleB, a highly 
conserved type III secretion system effector of A/E pathogens, suppresses NF-B activation, but the underlying 
mechanisms are unknown. We identified the mammalian glycolysis enzyme glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as an NleB interacting protein. Further, we discovered that GAPDH interacts with the 
TNF receptor associated factor 2 (TRAF2), a protein required for TNF--mediated NF-B activation, and 
regulates TRAF2 polyubiquitination. During infection, NleB functions as a translocated N-acetyl-D-glucosamine 
(O-GlcNAc) transferase that modifies GAPDH. NleB-mediated GAPDH O-GlcNAcylation disrupts the TRAF2-
GAPDH interaction to suppress TRAF2 polyubiquitination and NF-B activation. Eliminating NleB O-
GlcNAcylation activity attenuates C. rodentium colonization of mice. These data identify GAPDH as a TRAF2 
signaling cofactor and reveal a virulence strategy employed by A/E pathogens to inhibit NF-B dependent host 
innate immune responses. 
Highlights.  
 
The glycolysis enzyme GAPDH interacts with the TNF receptor associated factor, TRAF2 
The C. rodentium and E. coli virulence effector NleB binds GAPDH  
NleB uses its N-acetyl-D-glucosamine (O-GlcNAc) transferase activity to modify GAPDH  
GAPDH O-GlcNAcylation disrupts TRAF2-GAPDH complexes and attenuates NF-B signaling 
 
Introduction.  
 
Enterohemorrhagic E. coli (EHEC) are attaching/effacing (A/E) pathogens that are especially detrimental to 
human health because they cause hemorrhagic colitis and a type of renal failure (hemolytic uremic syndrome; 
HUS) for which therapy is limited. A related E. coli virotype, enteropathogenic E. coli (EPEC), is an important 
cause of infantile diarrhea. These human pathogens, as well as Citrobacter rodentium, a mouse pathogen that 
shares virulence strategies with E. coli (Deng et al., 2003), translocate virulence proteins (effectors) into 
intestinal epithelial cells using a type III secretion system (T3SS) to subvert the activity of various cell functions 
(Dean and Kenny, 2009). 
E. coli and C. rodentium T3SS effectors modulate the innate immune system, including host responses 
regulated by the transcription factor NF-B, via several different mechanisms (Rahman and McFadden, 2011). 
The NleB effector is highly conserved among the A/E pathogens (Kelly et al., 2006). NleB-deficient C. 
rodentium do not cause mortality (Wickham et al., 2007) or significant colonic hyperplasia (Kelly et al., 2006) in 
mice. These bacteria show markedly reduced colonization, as compared with wild-type (WT) C. rodentium, 
indicating the importance of NleB to C. rodentium virulence. NleB is associated with human EHEC outbreaks 
and the subsequent development of HUS (Wickham et al., 2006). The presence of NleB in atypical EPEC 
strains is associated with diarrheal disease (Bugarel et al., 2010). Thus, NleB plays an important role in the 
virulence of A/E pathogens. Two recent studies determined that NleB suppresses NF-B activation (Nadler et 
al., 2010, Newton et al., 2010). 
Here, we characterize a mechanism by which NleB inhibits NF-B signaling. NleB functions as a 
translocated N-acetyl-D-glucosamine (O-GlcNAc)-transferase that modifies the mammalian glycolysis enzyme 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). We provide evidence that GAPDH is a co-activator of 
the TNF receptor associated factor 2 (TRAF2) and that NleB-mediated GAPDH O-GlcNAcylation inhibits both 
TRAF2 activation and downstream NF-B signaling. 
 
Results.  
 
NleB inhibits NF-B activation by inhibiting TRAF2 polyubiquitination. WT C. rodentium colonized 
C57BL/6J mice to a greater magnitude than a strain bearing an isogenic deletion of NleB (nleB; Fig. S1A). 
Complementing nleB C. rodentium with a FLAG-tagged NleB expression plasmid (nleB/pnleB) restored 
bacterial colonization to nearly WT levels. WT C. rodentium was shed in mouse feces in greater numbers over 
the duration of infection, as compared with nleB C. rodentium (Fig. S1B). TNF serum concentrations were 
significantly higher in mice infected with WT C. rodentium, than in mice infected with nleB (Fig. 1A), indicating 
that NleB contributes to bacterial-induced host inflammation.  
NleB inhibits tumor necrosis factor (TNF)-induced NF-B activation (Newton et al., 2010, Nadler et al., 
2010), but its mechanism of action is not clear. We transfected HeLa cells with NleB-HA, stimulated these cells 
with TNF, and subsequently examined the extent of degradation of the NF-B inhibitor, IB. NleB prevented 
TNF-induced IB degradation, as well as the subsequent translocation of the NF-B p65 subunit to the 
nucleus (Fig. S1C).  
Deleting nleB from C. rodentium did not significantly alter nleE expression, another effector that inhibits 
NF-B activation (Fig. S1D; (Nadler et al., 2010)].  Both NleB and NleE, when transfected into HeLa cells, 
inhibited TNF-induced IBdegradation (Fig. S1E). Neither nleB nor nleE C. rodentium prevented 
IBdegradation during infection, by contrast to WT C. rodentium (Fig. S1F), indicating a potential 
coordinated activity between the effectors during C. rodentium infection. 
After TNF stimulation, the cytosolic death domain of the TNF receptor-1 (TNFR1) recruits proteins such 
as the TNFR-associated death domain protein (TRADD), the TNFR associated factor 2 (TRAF2), and the 
receptor-interacting protein 1 (RIP1) to form complexes that activate the NF-B pathway (Chen and Goeddel, 
2002). During this process, TRAF2, an E3 ubiquitin ligase, becomes polyubiquitinated and activates RIP1 
kinase activity. TRAF2 polyubiquitination was induced by TNF in control cells (Fig. 1B), whereas cells 
transfected with NleB-HA exhibited significantly reduced TRAF2 polyubiquitination. The TRAF2 interaction 
partner TRADD was still recruited to TRAF2 in NleB-transfected cells, suggesting how NleB inhibits TRAF2 
polyubiquitination is independent of TRADD.  
Bacterial infection induces production of additional TNFR ligands, including RANKL and CD40L (Zheng 
et al., 2008). These molecules can cause not only TRAF2 polyubiquitination, but also can promote its 
degradation. We transfected HeLa cells with TRAF2-FLAG and then infected these cells with C. rodentium 
strains that either express or lack NleB. Infecting cells with C. rodentium nleB induced TRAF2 degradation 
(Fig. 1C), with almost complete degradation of TRAF2 observed after 3 h. By contrast, TRAF2 was stable in 
cells infected with either WT or nleB/pnleB C. rodentium (Fig. 1C). TRAF2 degradation was mediated by 
ubiquitination, as nleB C. rodentium failed to induce the degradation of a TRAF2 RING mutant (Fig. 1D). 
Treating cells with the 26S proteasome inhibitor MG-132 also stabilized TRAF2 during infection (Fig. 1E). 
We hypothesized that NleB might target the TRAF2 polyubiquitination normally induced upon TNFR 
stimulation. TRAF2 polyubiquitination was prevented in cells infected with either WT or nleB/pnleB C. 
rodentium, but not nleB C. rodentium (Fig. 1E). NleB also inhibited the ubiquitination of RIP1, a substrate of 
TRAF2 Ub ligase activity [(Alvarez et al., 2010); Fig. 1F]. However, NleB did not directly inhibit TRAF2 self-
ubiquitination in vitro (Fig. S1G). Overall, our data instead suggested that NleB might target an unidentified co-
activator(s) of TRAF2 to prevent its polyubiquitination upon either TNFR stimulation or after bacterial infection, 
subsequently attenuating NF-B activation. 
 
NleB interacts with GAPDH. We did not obtain evidence that NleB interacts with TRAF2 from 
immunoprecipitation experiments (Fig. 1B). We conducted a proteomic screen to identify NleB interaction 
partner(s). By purified NleB-FLAG (Fig. 2A) and used it in affinity column experiments to identify a human 
protein of ~37 kDa that interacted with NleB (Fig. 2B). By using mass spectrometry and immunoblotting 
affinity-purified cell lysates, we identified this protein as human glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH; Fig. 2C-D), a component of the glycolysis pathway.  
GAPDH co-immunoprecipitated ectopically expressed NleB-HA, but not an HA-epitope control (Fig. 
2E). Infecting HeLa cells with C. rodentium strains expressing either NleB or NleC [an effector that also targets 
the NF-B pathway; (Pearson et al., 2011)], showed that NleB, but not NleC, immunoprecipitated with GAPDH 
during C. rodentium infection (Fig. 2F). We then developed an in vitro pulldown assay with purified 
recombinant proteins. NleB-FLAG, but not NleC-FLAG, binds directly to GAPDH (Fig. 2G), as NleB-FLAG was 
pulled down in vitro when mixed with GAPDH. 
We quantified the affinity of the NleB-GAPDH interaction in vitro by performing ELISAs. NleB-FLAG 
bound to immobilized GAPDH with an apparent dissociation constant (Kd) of 32 + 6 µM (Fig. 2H). By contrast, 
NleC-FLAG did not bind GAPDH with significant affinity. We did not detect significant changes in the 
abundance or in the cytoplasmic localization of GAPDH as a function of expressing NleB (data not shown). 
Some apoptotic stimuli generate nitric oxide, which subsequently causes GAPDH to be S-nitrosylated 
on its catalytic cysteine (C150) residue (Hara et al., 2005). We found that both WT and a C150S GAPDH 
mutant protein bound directly to NleB in vitro (Fig. 2I). Likewise, treating GAPDH with iodoacetate (IA), a small 
molecule inhibitor that modifies the GAPDH C150 sulfhydryl moiety and prevents disulfide bond formation 
(Harrison et al., 2003), at a concentration sufficient to inhibit GAPDH enzyme activity (10 µM; Fig. 2J), did not 
disrupt the GAPDH-NleB interaction in vitro (Fig. 2K). NleB binding to GAPDH did not inhibit GAPDH enzyme 
activity (Fig. 2J), either alone, or in concert with IA, indicating the NleB-GAPDH interaction is unlikely to affect 
host glycolysis directly. Overall, our data suggest that GAPDH is a eukaryotic interaction partner for NleB and 
this interaction is independent of GAPDH C150. 
 
GAPDH is required for TNF-induced NF-B activation. The role of GAPDH in stress response pathways 
has been studied previously (Hara et al., 2005). GAPDH participates in NF-B signaling (Bouwmeester et al., 
2004, Mookherjee et al., 2009), but the precise mechanism has not been elucidated. Transfecting siRNAs 
targeting the GAPDH-3’ UTR GAPDH depleted GAPDH abundance by approximately 50 % (Fig. S2A), 
activated multiple stress-induced signaling pathways (Fig. S2B), possibly due to the generation of reactive 
oxygen species (ROS; Fig. S2C) and the release of cytochrome c from mitochondria (Fig. S2D). 
Complementing GAPDH knockdown cells with either WT or C150S GAPDH-Myc prevented cytochrome c 
release (Fig. S2D) and reduced NF-B pathway activation (Fig. S2E-F).  
Complementing GAPDH knockdown cells with a GAPDH K160R plasmid, which encodes a form of 
GAPDH that cannot be acetylated by the p300/CREB binding protein [CBP; (Sen et al., 2008)], did not inhibit 
TNF-induced IB degradation (Fig. S2E). The K160 residue is essential for GAPDH binding to p300/CBP in 
the nucleus, an interaction that subsequently activates downstream apoptotic events. Because initiation of 
apoptosis typically leads to NF-B pathway activation (Van Antwerp et al., 1996), we conclude that K160 is not 
likely to be involved in TNF/NF-B signaling under the conditions of our assays.  
By contrast to WT and K160R GAPDH, complementing GAPDH knockdown cells with GAPDH C150S 
resulted in a ~30 % reduction in cellular ATP levels (Fig. S2G). This ~30 % reduction in [ATP] is not likely to 
contribute to the attenuation of NF-B activation, as a larger reduction in [ATP] was observed by inhibiting the 
rate-limiting glycolytic enzyme, pyruvate kinase, with potassium oxalate (PO; Fig. S2H). However, pyruvate 
kinase inhibition only caused a mild attenuation of TNF-induced NF-B activation (Fig. S2I).  
We hypothesized that GAPDH enzyme activity might be required for NF-B activation after TNF 
stimulation. Whereas complementation with WT GAPDH only slightly enhanced NF-B activation, 
complementation with GAPDH C150S instead significantly attenuated NF-B activation after TNF treatment 
(Fig. 3A). AP-1 luciferase activity was independent of GAPDH enzyme activity (Fig. 3B), suggesting a degree 
of specificity of GAPDH to the NF-B pathway. Expressing GAPDH C150S failed to restore TNF-induced IKK 
phosphorylation in GAPDH knockdown cells (Fig. 3C). We concluded that WT GAPDH is required for TNF-
induced NF-B activation. 
We used a pharmacological approach to evaluate the role of glycolysis on TNF-induced NF-B 
activation. We first pre-treated HeLa cells with IA to inhibit GAPDH and then treated these cells with TNF. 
While IA targets many other proteins containing reactive cysteines, including deubiquitinating peptidases, a 
number of other studies have used this reagent to inhibit both GAPDH and glycolysis (Fujiki et al., 2011, 
Wentzel et al., 2003). We also pre-treated cells with two other drugs that target glycolytic enzymes, either a 
pyruvate kinase inhibitor, potassium oxalate (PO), or a hexokinase inhibitor, 2-deoxy-D-glucose (2DG). 
Treating cells with either PO or with 2DG depleted [ATP] to ~20 % of that detected in untreated cells (Fig. 
S2H). By contrast, IA treatment only reduced [ATP] s ~2-fold. However, IA significantly inhibited GAPDH 
enzyme activity, whereas both 2DG and PO had less impact (Fig. S2J).  
Following TNF treatment, we conducted gene expression analyses. Our microarray (data not shown) 
and RT-PCR assays (Fig. S2K) showed that IA significantly inhibited TNF-induced increases in the expression 
of numerous NF-B-regulated genes. By contrast, neither 2DG nor PO significantly reduced the NF-B-
dependent gene expression normally induced by TNF. We reached similar conclusions by studying NF-B 
luciferase reporter activation after inhibitor treatment (Fig. S2I). By contrast to the NF-B-regulated genes, the 
expression of NF-B-independent genes was not impaired by drug treatment (Fig. S2K), again suggesting a 
degree of specificity for GAPDH activity in the NF-B pathway.  
Likewise, TNF failed to induce IB degradation and IKK phosphorylation in IA-treated cells, but had 
normal activity in cells treated with either PO or with bromopyruvate (BP), a hexokinase inhibitor (Fig. S2L). 
Both p38 and JNK phosphorylation were unaffected by IA (Fig. S2L). These data suggest that GAPDH 
regulates the NF-B signaling pathway using a mechanism distinct from its enzymatic role in glycolysis.  
 
GAPDH binds and activates TRAF2. TRAF2 is structurally similar to the E3 ligase Siah1, which interacts with 
GAPDH under stress (Hara et al., 2005). To determine whether GAPDH interacts with TRAF2, we co-
transfected TRAF2-FLAG with GAPDH-Myc and then immunoprecipitated TRAF2-FLAG. WT GAPDH was 
associated with TRAF2 and this interaction was enhanced by TNF (Fig. 4A). The association of endogenous 
GAPDH with TRAF2 was also promoted by TNF (Fig. 4B). Using in vitro pulldown assays with TRAF2-His, 
NleB-FLAG, and recombinant GAPDH, we determined that TRAF2 interacts directly with GAPDH, but not with 
NleB (Fig. 4C). GAPDH C150S did not immunoprecipitate with TRAF2 (Fig. 4A), suggesting the importance of 
the C150 residue for the interaction between GAPDH and TRAF2 in vivo. TRAF2 bound to WT GAPDH with an 
apparent Kd of 96 + 31 µM (Fig. 4D). TRAF2 did not bind to GAPDH C150S with significant affinity.  
We investigated whether the GAPDH-TRAF2 interaction is important for TRAF2 activity in response to 
TNF. After transfecting GAPDH siRNA and GAPDH-Myc plasmids, we treated cells with TNF and 
immunoprecipitated TRAF2. TRAF2 polyubiquitination was enhanced in cells expressing WT GAPDH (Fig. 
4E), whereas TRAF2 polyubiquitination was attenuated in cells either complemented with GAPDH C150S or in 
cells treated with IA. This phenotype appears to be unrelated to cellular ATP levels, as treating cells with PO 
(Fig. 4E, lane 4), which significantly reduced ATP stores (Fig. S2H) did not impair TRAF2 polyubiquitination. 
Thus, GAPDH binds TRAF2, its recruitment is dependent upon the C150 residue, and the interaction is 
enhanced by TNF.   
 
NleB is a glycosyltransferase that O-GlcNAcylates GAPDH. Analysis of the NleB amino acid sequence 
using the HHPred/HHSearch package (Soding et al., 2005), revealed that the central region of NleB is 
significantly similar (p-value 10-7) to GT-8 family glycosyltransferases. These glycosyltransferases have a 
conserved sequence and three-dimensional structure, represented by either a canonical or by a modified 
Rossman fold. These proteins are also characterized by a DxD catalytic signature, which chelates the divalent 
cation implicated in catalysis (Liu and Mushegian, 2003). The DxD signature, in the form of DAD tripeptide, is 
present in all NleB homologs we examined, as well as in the most closely related glycosyltransferases within 
the GT-8 family, namely the eukaryotic glycogenins (Fig. S3A). 
Glycogenins are glycosyltransferases that attach glucose to the growing glycogen chain (Lazarus et al., 
2011). Multiple sequence alignments indicated the conservation of several beta-strands and connecting -
helices that form the modified Rossmann fold in the glycogenin structure (Fig. S3A). Particularly well 
conserved are two beta-strands connected by the loop in which the conserved catalytic DxD motif is located, 
as well as the upstream motif between two alpha-helices that makes direct contacts to the uridine diphosphate 
(UDP), the dinucleotide substrate of human glycogenin 1. 
In eukaryotic cells, O-linked-N-acetylglucosamine (O-GlcNAc) regulates numerous cellular signaling 
networks, including the NF-B pathway (Yang et al., 2008), often in opposition with protein phosphorylation. O-
GlcNAc transferase (OGT) and O-GlcNAcase (OGA) regulate protein O-GlcNAcylation (Hart et al., 2011). OGT 
catalyzes the transfer of N-acetylglucosamine from UDP-GlcNAc to the hydroxyl oxygen of serine or threonine, 
whereas OGA removes O-GlcNAc from targeted proteins.  
We used an O-GlcNAc in vitro labeling assay to determine whether NleB possess glycosyltransferase 
activity. Alpha-crystallin, which contains a number of amino acids that can be O-GlcNAcylated, was used as a 
positive control. We incubated purified NleB-FLAG with GAPDH in the presence of UDP-GlcNAc and 
discovered that NleB-FLAG is capable of O-GlcNAcylating GAPDH (Fig. 5A). We confirmed these data by 
using an antibody (110.6) that specifically recognizes O-GlcNAcylation sites on proteins (Fig. 5B). The 
intensity of NleB-mediated GAPDH O-GlcNAcylation was proportional to the concentration of the sugar 
nucleotide donor UDP-GlcNAc (Fig. 5C).  
To investigate whether NleB O-GlcNAcylates GAPDH during bacterial infection, we infected HeLa cells 
for 3 h with C. rodentium. GAPDH O-GlcNAcylation was induced in cells infected with WT C. rodentium, but 
not in cells infected with nleB C. rodentium (Fig. 5D). GAPDH was not O-GlcNAcylated in control cells or in 
cells treated only with TNF (Fig. 5E). However, after transfecting NleB-HA, GAPDH was modified with O-
GlcNAc (Figs. 4E & 5E). NleB also O-GlcNAcylated GAPDH C150S in vivo (Fig. 4E) and in vitro (Fig. 5F), 
consistent with results suggesting GAPDH C150 is not required for the GAPDH-NleB interaction.  
To begin to identify GAPDH O-GlcNAcylation sites, we first considered several GAPDH residues that 
are modified by cellular enzymes. Although we did not detect OGT in TRAF2-GAPDH complexes (Fig. 4E), 
OGT has been suggested to O-GlcNAcylate GAPDH on T229 (Park et al., 2009). We mutated T229 (T229A) 
and a neighboring threonine residue, T211 (T211A), to determine if NleB targets them for modification. 
However, neither mutant differed in NleB-mediated GAPDH O-GlcNAcylation (Fig. 5F). GAPDH is 
phosphorylated by protein kinase B (AKT) on T237, which prevents GAPDH nuclear translocation and 
suppresses GAPDH-mediated apoptosis (Huang et al., 2011). We also mutated T237 (T237A), as well as the 
neighboring residues S241 (S241A), T246 (T246A), and T277 (T277A). However, we still did not detect 
significant changes to NleB-mediated GAPDH O-GlcNAcylation, indicating there may be other or multiple 
GAPDH residues targeted by NleB (Fig. 5F).  
To confirm further that NleB is an O-GlcNAc transferase, we mutated the predicted catalytic site 
221DAD223 of NleB to 221AAA223. The NleB 221DAD-AAA223 mutant [hereafter designated NleB(AAA)] failed to O-
GlcNAcylate GAPDH proteins either in vivo (Fig. 4E & Fig. 5E) or in vitro (Fig. 5G). Expressing an NleB 
mutant in which the modified Rossmann fold was deleted (202) also abolished the O-GlcNAcylation of 
GAPDH by NleB (Fig. 5G). However, GAPDH, in the presence or absence of NleB and UDP-GlcNAc did not 
directly inhibit TRAF2 self-ubiquitination in vitro (Fig. S3B). 
O-GlcNAcase catalyzes the cleavage of O-GlcNAc from glycosylated proteins. Treating cells with an O-
GlcNAcase inhibitor, thiamet G (TMG), increased total cellular protein O-GlcNAcylation (Fig. 5E). We tested 
whether O-GlcNAcylation of GAPDH by NleB is enhanced by TMG treatment. Although we did not detect any 
basal GAPDH O-GlcNAcylation in our experimental system, we found that GAPDH O-GlcNAcylation was 
significantly enhanced by NleB (Fig. 5E), and further enhanced after TMG treatment. By contrast, the 
NleB(AAA) mutant failed to induce GAPDH O-GlcNAcylation, irrespective of TMG. Thus, NleB activity appears 
to be linked to cellular O-GlcNAc concentrations. These experiments were conducted using ectopic expression 
of NleB and NleB(AAA) to allow specific analysis of the TNF/TRAF2 pathway, in the absence of other potential 
inducers generated during bacterial infection (e.g. IL-1, LPS). 
Most proteins that are O-GlcNAcylated by OGT are sensitive to glucose concentrations because this 
sugar affects the activity of the hexosamine biosynthetic pathway (Hart et al., 2011). In our system, total 
protein O-GlcNAcylation was decreased in cells cultured in hypoglycemic conditions, as compared with 
hyperglycemic conditions (Fig. S3C). However, the level of GAPDH O-GlcNAcylation mediated by NleB did not 
change significantly in the different glucose conditions (Fig. S3D), indicating that the activity of NleB may be 
largely insensitive to changes in UDP-GlcNAc concentrations. Taken together, our data suggest that NleB is a 
translocated glycosyltransferase that modifies host GAPDH with O-GlcNAc.  
 
NleB O-GlcNAc transferase activity disrupts the GAPDH-TRAF2 interaction and inhibits NF-B activity. 
We immobilized TRAF2-His on Ni-NTA agarose and then applied either purified GAPDH or NleB-FLAG + 
UDP-GlcNAc to assess the binding interactions among these three proteins. More NleB-FLAG was pulled 
down by GAPDH/TRAF2 in the absence of UDP-GlcNAc than when UDP-GlcNAc was present (Fig. 6A). 
When incubated with NleB and UDP-GlcNAc, only the GAPDH that had dissociated from TRAF2 possesses a 
significant O-GlcNAcylation signal, as compared with GAPDH still bound to TRAF2 (Fig. 6B). We therefore 
hypothesized that NleB might interact with GAPDH to disrupt the formation of TRAF2-GAPDH complex through 
its O-GlcNAc transferase activity. Indeed, while WT NleB blocked the association of GAPDH with TRAF2 after 
TNF treatment, the glycosyltransferase-deficient mutant NleB(AAA) failed to do so (Fig. 4E).  
GAPDH that had been previously labeled in vitro with O-GlcNAc by NleB had significantly lower affinity 
for TRAF2, as compared with unlabeled GAPDH (Fig. 6C), while adding excess UDP-GlcNAc to the ELISA 
had no discernible impact on TRAF2-GAPDH affinity (Fig. 6C). Thus, the glycosyltransferase activity of NleB 
appears to disrupt the TRAF2-GAPDH interaction, as GAPDH O-GlcNAcylation by NleB significantly reduced 
the affinity between GAPDH and TRAF2 in vitro (Fig. 6) and prevented their association in vivo (Fig. 4). 
We next examined whether NleB-mediated GAPDH O-GlcNAcylation is essential for NleB to inhibit NF-
B pathway activation. By contrast to WT NleB, NleB(AAA) did not prevent IB degradation stimulated by 
TNF (Fig. 5E). NleB202 mutant also failed to block IB degradation and p65 nuclear translocation (Fig. 6D). 
These data are consistent with our findings that TRAF2 polyubiquitination was not impaired by the 
glycosyltransferase-deficient mutant NleB(AAA) upon TNF stimulation, by contrast with WT NleB (Fig. 4D & 
5E).  
WT NleB completely abolished TRAF2 polyubiquitination induced by TNF in TMG-treated cells, 
whereas NleB(AAA) had no impact (Fig. 5E, lanes 7 vs. 8). Although TMG treatment alone did not prevent 
IB degradation and NF-B activation, it stabilized IB in the presence of WT NleB, but not in the presence 
of NleB(AAA) (Fig. 5E). NleB exhibited a more robust inhibition of NF-B in cells treated with TMG as 
compared with cells not treated with TMG (Fig. 6E). NF-B activity was promoted by TMG treatment, 
consistent with previous reports (Kawauchi et al., 2009). Neither NleB nor TMG altered AP-1 activation (Fig. 
6F), indicating that NleB-mediated GAPDH O-GlcNAcylation is specifically involved in the NF-B signaling 
pathway.  
To evaluate whether the O-GlcNAc transferase activity of NleB is important to C. rodentium virulence, 
we infected mice with C. rodentium strains expressing either WT NleB (nleB/pnleB) or the O-GlcNAc 
transferase-deficient NleB mutant, NleB(AAA) [nleB/pnleB(AAA)]. Mice infected with nleB/pnleB(AAA) C. 
rodentium strain showed a ~100-fold reduction in colonization magnitude after 7 days, as compared with C. 
rodentium expressing WT NleB (Fig. 6G). While the reduction in colonization was not as great as compared 
with the impact of deleting the entire nleB gene, this result demonstrated that a major role of C. rodentium host 
colonization mediated by NleB is due to its O-GlcNAc transferase activity.  
Consistent with this phenotype, the NleB(AAA) mutant failed to suppress NF-B activation during C. 
rodentium infection of HeLa cells, as compared with WT and nleB/pnleB C. rodentium, even in the absence of 
exogenous TNF (Fig. 6H). Over-expressing GAPDH ectopically in cells that were subsequently infected with C. 
rodentium strains expressing NleB was able to restore partially NF-B luciferase activity (Fig. 6H). By contrast, 
GAPDH over-expression did not increase NF-B activity in cells infected with nleB C. rodentium, suggesting a 
potential saturation of the interaction between GAPDH and endogenous TRAF2. Because GAPDH over-
expression also did not significantly increase basal NF-B activity in uninfected cells, our data suggest that the 
O-GlcNAc transferase activity of NleB is essential for its ability to inhibit NF-B activation and to enhance C. 
rodentium colonization and virulence through a mechanism involving the modification of GAPDH (Fig. 7). 
Further, these data suggest that GAPDH might play a role as a general stress sensor by participating in NF-B 
signaling. 
 
Discussion.  
 
Several studies have suggested GAPDH may be involved in regulating innate immunity. GAPDH is enriched 
with the NF-B family member c-Rel and with other NF-B signaling molecules (Bouwmeester et al., 2004). 
Mookherjee et al also predicted that GAPDH interacts with molecules in the NF-B pathway (Mookherjee et al., 
2009). GAPDH binding to TRAF2 was enhanced under stress conditions, similar to the interaction between 
Siah1 and GAPDH (Hara et al., 2005). Our data suggest that GAPDH may be a co-activator of TRAF2, 
perhaps acting at an early step in the TNF/NF-B signaling pathway, before E1 and E2 enzymes are recruited 
to TRAF2. How GAPDH facilitates TRAF2 polyubiquitination is unknown and will require significant future 
structure-function experiments. We raise the possibility that there may be a network of factors recruited to 
TRAF2 upon TNFR stimulation that is important to regulating TRAF2 activation, among these, GAPDH. 
While TNF activates the NF-B, p38, and JNK signaling pathways through TRAF2, the role of TRAF2 
ubiquitination is more essential to downstream JNK, than to either p38 or NF-B signaling (Habelhah et al., 
2004), possibly due to the redundant role of TRAF2 and TRAF5 in NF-B activation (Tada et al., 2001, Yeh et 
al., 1997). Our data show that GAPDH-mediated TRAF2 ubiquitination is required for NF-B activation, but not 
for JNK and p38 activation. GAPDH may catalyze a specific form of TRAF2 ubiquitination or may promote a 
different modification that somehow enhances the TRAF2 polyubiquitination activity required for downstream 
NF-B activation. 
We found that the GAPDH C150 residue is essential to the GAPDH-TRAF2 interaction. This is 
consistent with previous work, which also showed that C150 is involved in the GAPDH activities that are 
independent of glycolysis (Hara et al., 2005). Although it is not clear how C150 contributes to GAPDH 
involvement in these processes, this active site residue is redox-sensitive and is often modified under stress 
conditions.  
Various studies have also shown that cellular signaling and protein glycosylation are tightly linked 
(Wellen and Thompson, 2012). O-GlcNAcylation requires UDP-GlcNAc, the final product of the hexosamine 
biosynthetic pathway. Evidence that O-GlcNAcylation is important in regulating immune signaling pathways is 
emerging. Enhanced glucose metabolism induces O-GlcNAcylation of NF-B components and increases NF-
B activity (Kawauchi et al., 2009, Yang et al., 2008). For example, O-GlcNAcylation of TAB1 after IL-1 
stimulation is essential for TAK1 activation and NF-B activation (Pathak et al., 2012). In agreement with these 
studies, we found that inhibiting OGA increased NF-B activity after TNF stimulation.  
We showed that GAPDH is O-GlcNAcylated by the T3SS effector NleB, a glycogenin-related 
glycosyltransferase. O-GlcNAcylated GAPDH fails to interact with TRAF2 in vivo. GAPDH O-GlcNAcylation by 
OGT on T227 has been reported before (Park et al., 2009). However, we did not detect OGT-mediated 
GAPDH O-GlcNAcylation under our experimental conditions. We are currently identifying NleB-mediated O-
GlcNAcylation site(s) on GAPDH to clarify the precise mechanism by which GAPDH functions in the NF-B 
signaling pathway.  
We have considered the possibility that NleB activity could be somehow coordinated with changes to 
host cell metabolism associated with infection (Borregaard and Herlin, 1982, Cramer et al., 2003). However, 
our preliminary efforts to address this complex issue indicated that NleB-mediated GAPDH O-GlcNAcylation is 
largely insensitive to different glucose concentrations, likely due to the maintenance of relatively high 
concentrations of UDP-GlcNAc. Therefore, NleB does not appear to share the same mechanism as OGT, 
which by contrast, is sensitive to glucose concentrations (Hart et al., 2011). However, inhibiting OGA with TMG 
augmented GAPDH O-GlcNAcylation by NleB, leaving open the possibility that NleB co-ordinately regulates 
protein O-GlcNAcylation in concert with the mammalian enzymes OGT and OGA.  
Clostridial toxins glucosylate and inhibit GTPases of the Rho and Ras superfamily (Kelly and LaMont, 
2008). Legionella pneumophila Lgt proteins glucosylate the eukaryotic elongation factor 1A to block protein 
synthesis (Belyi et al., 2006). Like NleB, these toxins all belong to GT-A family of glycosyltransferases and 
contain at least one Rossmann-like fold and the DXD catalytic motif. We have yet to characterize the substrate 
specificity of NleB and it is possible that NleB may be able to utilize other nucleotide sugars to glycosylate 
GAPDH. It remains to be determined if NleB interacts with other host proteins, and if so, whether NleB O-
GlcNAcylates these proteins. We note that several other proteins detected in GAPDH immunoprecipitates 
appear to be more heavily O-GlcNAcylated in the presence, than in the absence, of NleB (Fig. 5D). 
The difference in colonization magnitude between the nleB strain and nleB/pnleB(AAA) is not 
unexpected. NleB contains an additional DAD motif in its N-terminus, which could also contribute to the ability 
of NleB to control TNF-induced NF-B activity. It will be interesting to examine the contribution of other NleB 
functional domains to bacterial virulence. It is also possible that NleB has functions that are independent of its 
glycosyltransferase activity and its targeting of the NF-B pathway. 
The impact of NleB on NF-B is tightly linked with its O-GlcNAc transferase activity directed against 
GAPDH. GAPDH fails to interact with TRAF2 in the presence of NleB, resulting in attenuated TRAF2 
polyubiquitination. This is similar to the phenotype of cells expressing GAPDH C150S, which also fails to bind 
TRAF2 and fails to promote TRAF2 polyubiquitination. Furthermore, the NleB(AAA) mutant is unable to O-
GlcNAcylate GAPDH and does not inhibit NF-B activation. Our discovery that NleB utilizes UDP-GlcNAc to 
disrupt TRAF2 complex formation represents a mechanism by which enteric pathogens inhibit host innate 
immunity.  
 
Experimental procedures.    
 
Bacterial strains, plasmids, reagents, and oligonucleotides. Reagents were used according to 
manufacturer’s recommendations and are described in the supplemental information. Bacterial strains, 
plasmids, and oligonucleotide sequences are also described in supplemental information. 
 
RNA interference. Three pmol of scrambled siRNAs or siRNAs directed against GAPDH were transfected into 
HeLa cells using Lipofectamine 2000. The transfection mixture was replaced with complete growth media after 
6 h and cells were incubated for a further 60 h prior to harvest. Knockdown specificity was confirmed using 
immunoblotting. GAPDH siRNA sense-strand sequences were: UTR-1: 5’-AGCACA2GAG2A2GAGAGAGAC3T; 
UTR-2: 5’- CATGTAC2ATCA2UA3GTAC3TG; UTR-3: CTC2TCACAGT2GC2ATGTAGA3. 
 
Affinity columns and protein identification by LC-ESI-MS/MS. Both affinity column and mass spectrometry 
experiments were conducted essentially as described before (Gao et al., 2009). Bands excised from protein 
gels were digested in-gel with trypsin at 37 °C overnight. Spectra were obtained in the positive ion mode with a 
nano ESI-Q-Tof micro mass spectrometer.  
	
In vitro pulldown assays. 1.0 mg of purified NleB-FLAG or NleC-FLAG were immobilized on FLAG M2-
conjugated beads and then incubated with 1.0 mg GAPDH for 4 h at 4 °C. Beads were centrifuged and 
washed three times with 20 mM HEPES, pH 7.9, 150 mM KCl, 0.2 mM EDTA, 0.1 % NP-40, 10 % glycerol, 1.0 
mM DTT). SDS-PAGE sample buffer was added and samples were analyzed using immunoblotting. 
 
O-GlcNAcylation assays. NleB-FLAG or NleC-FLAG proteins (500 ng) were incubated with 500 ng GAPDH at 
4 °C for 18 h + 1 mM UDP-GlcNAc. O-GlcNAcylated proteins were detected using the Click-iT O-GlcNAc 
Enzymatic Labeling System (Invitrogen). Alternatively, proteins were incubated in 50 mM Tris–HCl, pH 7.5, 1 
mM DTT, 10 mM MnCl2, 1 mM UDP-GlcNAc for 4 h at room temperature.  
 
GAPDH enzyme activity. GAPDH activity in HeLa cells was measured by using a fluorescence-based assay 
kit (KDalertTM GAPDH) according to the manufacturer’s recommendations. Briefly, 1.0*104 cells were treated + 
10 µM IA for 40’. Cells were resuspended in ice-cold Cell Lysis Buffer and incubated for 20’. Aliquots were 
transferred to 96-well plates and changes in fluorescence were measured every 4’ in a fluorescence plate 
reader. GAPDH activity was determined through comparison to protein standards. For in vitro GAPDH 
enzymatic activity assays, 0.1 g GAPDH was pre-incubated with 0.1 g NleB-FLAG or NleC-FLAG with 1 mM 
IA and or 0.1 mM UDP-GlcNAc. 
 
Luciferase assays. Luciferase assays were conducted as described (Gao et al., 2009). HeLa cells were co-
transfected at a ratio of 10:1 (1.0 g total DNA) with a luciferase reporter construct (NF-B or AP-1) together 
with the renilla luciferase pTKRL plasmid, cultured for 48 h, in the presence or absence of TNF. Cells were 
lysed with passive lysis buffer and lysates were analyzed according to the protocol from Dual-Luciferase Kit. 
The fold-induction was calculated as [relative FU stimulated)/(relative FU unstimulated] samples. Luciferase 
assays were performed in triplicate with at least three independently transfected cell populations.  
 
TRAF2 ubiquitination assay. Ubiquitination assays were performed using enzymes obtained from Boston 
Biochem, supplemented with NleB (50 nM), and UDP-GlcNAc (1 mM). His-E1(100 nM), Ubc/Uev1a (100 nM), 
His-TRAF2 (50 nM), ubiquitin (2 µM), and ATP (2 mM) were incubated in 5 mM MgCl2, 50 mM HEPES, pH 7.5, 
10 mM NaCl, 1 mM DTT) at 30 °C for 1 h, in the presence or absence of GAPDH (50 nM), NleB (50 nM), and 
UDP-GlcNAc (1 mM). Reactions were terminated by adding SDS-PAGE loading buffer and boiled at 95 °C for 
5’. TRAF2 ubiquitination was determined using immunoblotting with -ubiquitin antibody. 
 
ELISAs. TNF concentrations in mouse sera were measured using a mouse TNF Quantikine ELISA Kit 
according to the manufacturer's instructions. Protein binding studies were conducted as previously described, 
(Pham et al., 2012). 
 
Mouse infections. All animal experiments were performed according to Institutional Animal Care and Use 
Committee-approved protocols (Animal Welfare Assurance #A3237-01) and conducted as previously 
described (Gao et al., 2009). 
 
Bioinformatics. Probabilistic searches using profile-Hidden Markov Models were done using the 
HHPred/HHSearch package (Soding et al., 2005). Multiple sequence alignments were obtained using the 
PROMALS3D software (Pei et al., 2008), seeded with NleB and their glycogenin-related homologs.  
 
Statistics. RT-PCR, luciferase, ELISA, and enzyme activity data were analyzed statistically using one-way 
ANOVA with Bonferonni’s multiple comparison tests. C. rodentium colonization data were analyzed using the 
Kruskal-Wallis test. P values < 0.05 were considered significant. 
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Figure Legends.  
 
Figure 1, see also Figure S1. NleB inhibits NF-κB activation by preventing TRAF2 polyubiquitination. A. 
TNF concentrations (pg/ml; mean + SEM, n = 8) in serum (7 d post-infection) from uninfected mice or mice 
infected with indicated C. rodentium strains. Asterisks indicate significantly different [TNF] as compared with 
WT infection (one-way ANOVA with Bonferonni’s multiple comparison test). B. TRAF2-FLAG was co-
transfected with NleB-HA and immunoprecipitated using -FLAG antibody. Immunoprecipitates were 
immunoblotted for FLAG, TRADD, ubiquitin, and HA. LC, antibody light chain. C. HeLa cells were transfected 
with TRAF2-FLAG and then infected with C. rodentium for 1 or 3 h. TRAF2 and IB abundance were 
analyzed using immunoblotting. D. HeLa cells were transfected with either TRAF2-FLAG or RING TRAF2 
(TRAF2-RM) plasmids and then infected with C. rodentium for 3 h.  E. HeLa cells were transfected with 
TRAF2-FLAG, pre-treated with 10 µM MG-132 for 2 h, and then infected with C. rodentium. TRAF2 was 
immunoprecipitated and polyubiquitination was assessed using immunoblotting. F. RIP1 was co-transfected 
with NleB-HA and immunoprecipitated using -RIP1 antibody. Immunoprecipitates were immunoblotted for 
ubiquitin and RIP1. Data are represented as mean + SEM, n = 3. Asterisks indicate significantly different 
[RIP1-Ub] as compared with TNF treatment (Bonferonni’s). 
 
Figure 2. NleB binds GAPDH. A. NleB-FLAG protein purity assessed by Coomassie Blue staining after 12 % 
SDS-PAGE. B. HeLa cell lysates were incubated with purified NleB-FLAG pre-bound to FLAG M2 beads and 
analyzed by SDS-PAGE. The band indicated with an asterisk was excised and analyzed using mass 
spectrometry. C. GAPDH amino acid sequence. Tryptic peptides identified by mass spectrometry are indicated 
in bold. D. Affinity column samples were analyzed using immunoblotting with -GAPDH antibody. E. NleB-HA 
was transfected. GAPDH was immunoprecipitated and immunoblotted for GAPDH and HA. F. 
Immunoprecipitation of GAPDH from HeLa cells by translocated NleB- or NleC-FLAG after C. rodentium 
infection for 0.5, 1 or 3 h. Samples were immunoprecipitated with -GAPDH antibody and immunoblotted for 
FLAG and GAPDH. G. FLAG-tagged NleB or NleC were coupled to M2 beads and incubated with GAPDH. 
Samples were analyzed using IRDye Blue protein staining after electrophoresis through 12 % SDS-PAGE. H. 
ELISA plates were coated with 2 µg GAPDH. Coated plates were overlaid with increasing amounts of NleB- or 
NleC-FLAG. Protein binding was detected using -FLAG antibody and 1-Step Ultra TMB-ELISA solution. 
Absorbance at 450 nm was measured (mean + SEM, n = 4). I. In vitro pulldown assay for the interaction 
between GAPDH C150S and NleB. Purified GAPDH- and GAPDH C150S-His proteins were incubated with 
NleB-FLAG or NleC-FLAG proteins prebound to M2 beads. J. GAPDH enzyme inhibition by iodoacetate (IA; 
mean + SEM, n = 3). Asterisks indicate significantly different GAPDH activity (Bonferroni’s). K. Impact of IA on 
GAPDH-NleB binding was measured using in vitro pulldown assay. GAPDH was treated with IA and then 
incubated with NleB-FLAG prebound to M2 beads.  
 
Figure 3, see also Figure S2. GAPDH is essential for TNF-induced NF-B activation. A. NF-B luciferase 
activity as a function of GAPDH complementation (mean + SEM, n = 3). Asterisks indicate significantly different 
luciferase activity between GAPDH WT and C150S complementation (t-test). B. AP-1 luciferase activity as a 
function of GAPDH complementation (mean + SEM, n = 3). C. Analysis of IKK phosphorylation and IB 
degradation in GAPDH knockdown cells complemented with WT GAPDH or GAPDH C150S. HeLa cells were 
co-transfected with GAPDH siRNA, as well as with IKK-FLAG and either WT GAPDH-Myc or GAPDH-C150S-
Myc plasmids, and then stimulated with TNF.  
 
Figure 4. GAPDH interacts with TRAF2. A. HeLa cells were transfected with TRAF2-FLAG + GAPDH-Myc 
plasmids, immunoprecipitated using -FLAG antibody, and then immunoblotted using -Myc antibody. B. 
Experiment was performed as described in panel A, except that endogenous GAPDH association with TRAF2 
was monitored using -GAPDH antibody. TNF treatment time is indicated. C. TRAF2-His protein was coupled 
to Ni-NTA agarose and incubated with GAPDH and/or NleB-FLAG + 1.0 mM UDP-GlcNAc. The bound and 
flow-through (FT) samples are indicated. D. ELISA plates were coated with 2 µg of either WT GAPDH or 
C150S GAPDH. Coated plates were overlaid with increasing amounts of TRAF2. Protein binding was detected 
using -TRAF2 antibody (mean + SEM, n = 4). E. HeLa cells were transfected and treated 60 h later with 
indicated glycolysis enzyme inhibitors. Cell lysates were immunoprecipitated using -FLAG antibody to capture 
TRAF2-FLAG and immunoblotted for ubiquitin and GAPDH-Myc. Additional immunoprecipitations were 
conducted using -Myc antibody to capture GAPDH-Myc and immunoblotted for O-GlcNAc and OGT. 
 
Figure 5, see also Figure S3. NleB O-GlcNAcylates GAPDH. A. Detection of GAPDH O-GlcNAcylation by 
NleB using 5-carboxytetramethylrhodamine (TAMRA). B. Detection of GAPDH O-GlcNAcylation by NleB using 
-O-GlcNAc antibody (110.6). C. GAPDH O-GlcNAcylation as a function of [UDP-GlcNAc]. NleB- or NleC-
FLAG was incubated with GAPDH and UDP-GlcNAc. Proteins were analyzed by SDS-PAGE and 
immunoblotted for the O-GlcNAcylation using -GlcNAc antibody. D. GAPDH O-GlcNAcylation during bacterial 
infection. HeLa cells were infected with C. rodentium WT or nleB for 1 or 3 h. Cell lysates were 
immunoprecipitated with -GAPDH antibody and analyzed for O-GlcNAcylation. Asterisks indicate other 
proteins detected in GAPDH immunoprecipitates more heavily O-GlcNAcylated in the presence NleB. E. 
NleB(AAA) does not O-GlcNAcylate GAPDH. HeLa cells were co-transfected with NleB, TRAF2, and GAPDH 
plasmids for 60 h and treated with 20 µM TMG for 8 h + TNF (20’). Cell lysates were immunoprecipitated for 
TRAF2-FLAG or GAPDH-Myc. Cell lysates were also immunoblotted for total protein O-GlcNAcylation. F. 
Purified GAPDH mutant proteins were incubated with NleB-FLAG and UDP-GlcNAc. GAPDH O-GlcNAcylation 
was analyzed using -GlcNAc antibody. G. FLAG-NleB WT and mutants were purified and incubated with WT 
GAPDH. Samples were analyzed using SDS-PAGE and immunoblotted with -GlcNAc and -GAPDH 
antibodies. 
 
Figure 6. NleB O-GlcNAc transferase activity is essential for inhibiting the NF-κB pathway. A. TRAF2-
His was coupled to Ni-NTA beads and then incubated with NleB-FLAG and GAPDH. UDP-GlcNAc (1 mM) was 
added where indicated. Bound and flow-through (FT) proteins were stained with IRDye Blue. B. O-
GlcNAcylation of free (FT) and TRAF2-associated GAPDH. Samples were immunoblotted using -GlcNAc 
antibody. C. ELISA plates were coated with 2 µg of either unmodified GAPDH or GAPDH that had been 
labeled in vitro by O-GlcNAc after incubation with NleB and UDP-GlcNAc. Coated plates were overlaid with 
increasing amounts of TRAF2 + 100 µM UDP-GlcNAc. Protein binding was detected using -TRAF2 antibody 
(mean + SEM, n = 4). D. Immunoblotting of IB and p65 nuclear translocation in the presence of NleB(202). 
E. NF-B luciferase activity (mean + SEM, n = 4) + NleB and TMG. HeLa cells were co-transfected with 
luciferase reporters and NleB-HA or control plasmids for 60 h, and treated with TMG for 8 h before treating with 
TNF for 20’. Asterisks indicate significantly different luciferase activity, t-test. F. AP-1 luciferase activity (mean 
+ SEM, n = 4) + NleB and TMG. G. Colonization (log10 CFUs / g colon) of indicated C. rodentium strains (7 d 
post-gavage) in C57BL/6J mice (n = 6-7). Asterisks indicate significantly different colonization magnitude as 
compared with WT; Kruskal-Wallis test. H. NF-B luciferase activity as a function of C. rodentium infection and 
GAPDH-Myc over-expression (mean + SEM, n = 4). HeLa cells were co-transfected with GAPDH-Myc or Myc-
epitope control plasmids with NF-B luciferase reporter plasmids for 48 h and then infected with the indicated 
C. rodentium strains for 3 h. Asterisks indicate significantly different luciferase activity between GAPDH-Myc or 
Myc-epitope transfection. 
 
Figure 7. Working model for the role of GAPDH in the NF-B signaling pathway and its targeting by 
NleB to attenuate TRAF2 activation. After TNF stimulation through TNFR, GAPDH is induced to the TRAF2 
complex, promoting TRAF2 polyubiquitination and activating the NF-B pathway through IKK. Drug treatments 
and mutagenesis studies show that this recruitment is dependent upon GAPDH enzyme activity. During 
infection, NleB binds GAPDH and modifies it with O-GlcNAc. O-GlcNAcylated GAPDH is unable to bind 
TRAF2, reducing downstream NF-B activation. NleB(AAA) is deficient in O-GlcNAc transferase activity and 
unable to inhibit GAPDH binding to TRAF2. Whether NleB directly impacts host cell metabolic pathways and 
the identification of other substrates for its O-GlcNAcylation activity remain to be determined. 
 
 
